Reduction in CRP and LDL-C and Cardiovascular Event Rates After Initiation of Rosuvastatin (JUPITER)

This prospective analysis of the JUPITER trial examined whether the degree of reduction in hs-CRP and LDL-C independently predicted cardiovascular event rates in rosuvastatin-treated patients, testing whether dual target achievement (LDL-C <70 mg/dL and hs-CRP <2.0 mg/L) conferred greater benefit than achieving either target alone.

Participants who achieved both LDL-C <70 mg/dL and hs-CRP <2.0 mg/L at 1 year had the lowest subsequent cardiovascular event rates — substantially lower than those who achieved LDL-C reduction alone. Those who reduced LDL-C without achieving hs-CRP suppression had intermediate outcomes. The event rate in those achieving both targets was 79% lower than in placebo controls.

The finding supports the inflammatory hypothesis of atherothrombosis at the individual patient level: it is not simply the degree of LDL-C lowering that determines residual risk, but the combination of lipid and inflammatory target achievement. Statin therapy reduces both — through LDL-C lowering and pleiotropic anti-inflammatory effects — and patients who respond strongly on both dimensions do best.

The clinical implication is that hs-CRP monitoring after statin initiation may identify patients with residual inflammatory risk despite lipid control, who might benefit from additional anti-inflammatory strategies (now including colchicine and potentially canakinumab).

We rate the evidence strong. A well-designed prospective JUPITER analysis establishing that dual LDL-C and CRP reduction produces the greatest cardiovascular risk reduction — supporting inflammation as an independent therapeutic target.